Short communication · 25 Jan 2022
Conference abstract
Factors affecting bioavailability and bioequivalence
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
I ntrinsic and extrinsic factors affecting bioavailability and bioequivalence are well established. However there is a necessity to understand many situations, where bioavailability may be an extremely important issue. Examples of products whose bioavailability may not be easily predicted include oral immediate release products with systemic action when one or more of the following criteria apply: ? Critical use medicines. ? Narrow therapeutic range ? Pharmacokinetics complicated by variable or incomplete absorption window, non linear pharmacokinetics, presystemic elimination / first pass metabolism. ? Low solubility, instability, low permeability. ? There is a high ratio of excipients to active ingredients. In such situations the bioavailability must be studied in a close manner. Further there are many situations such as the coadministration of docetaxel and cyclosporine and fixed dose combinations of isoniazid, rifampicin and pyrazinamide where interesting changes in bioavailability occur. Rifampicin shows variable bioavailability from solid oral dosage forms and the reasons for this variable absorption reported in literature vary from extrinsic formulation factors to intrinsic variability in rifampicin absorption. P-Glycoprotein was shown to have a role in the enhanced oral bioavailability of docetaxel by coadministration of cyclosporine. Cyclosporine is an efficacious inhibitor of P-Glycoprotein and cytochrome P 450 (CYP) 3 A 4 in the gut wall and liver. This presentation aims to focus on situations of irregular bioavailability in the case of certain drugs or altered bioavailability in certain situations. PDF HTML
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
Factors affecting oral bioavailability
Conference proceeding · 2019
2020 Conference Announcement on Bioavailability and Bioequivalence, November 26-27, 2020 | Istanbul, Turkey
Article · 29 Aug 2025
Clinical Pharmacology A Pillar for Bioequivalence and Bioavailability Studies
Article · 29 Aug 2025
Pharmacokinetic Comparison A Critical Tool in Assessing Bioavailability and Bioequivalence
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Article · 5 Oct 2026
Long COVID in pediatric and young adult patients: a review of evaluation for microvascular changes, endothelial dysfunction, and arterial stiffness
Article · 12 Jun 2026
Advances in Bioavailability Through Innovative Drug Delivery Systems and Formulation Technologies
Article · 12 Jun 2026
Bioequivalence Study Design and Methodological Approaches in Generic Drug Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “J. Vijaya Ratna”
